Merck & Co., Inc. (MRK) Up 4.5% — Time to Put Capital to Work Here?
Merck & Co., Inc. (MRK) is gaining ground this Thursday, last changing hands at $147.29 on the NYSE — a $6.36 gain from the prior close of $140.93. The advance puts the stock within about 6.1% of its 52-week high of $156.92, a level set on August 25, 2026. That sets up a clear path back toward the top of its range for a pharmaceutical heavyweight carrying a $347.70 billion market value.
Volume so far stands at roughly 4.22 million shares against a 90-day average of about 10.03 million. With the session still underway, turnover is running at roughly 42% of a typical full day while the price has already tacked on more than four percentage points.
Why Merck & Co., Inc. Price is Moving Higher
The move comes down to a decisive Q3 beat and a raised outlook. Merck reported on October 29, posting adjusted EPS of $2.49 against analyst estimates of roughly $2.09. That is a margin of about 19%, the kind of upside that forces a fast repricing in a stock of this size. Revenue reached $18.09 billion versus the roughly $17.28 billion consensus, up 5% year over year. Adjusted EPS slipped 3% from $2.58 in the prior-year quarter, and GAAP net income declined 12% to $5.07 billion. The market looked past those comparisons and focused on how far results cleared expectations.
The product mix gave the beat its credibility. Keytruda and Keytruda Qlex together generated $8.60 billion in sales, up 6%, with the newer Qlex formulation already contributing $830 million. Winrevair, Merck's pulmonary arterial hypertension therapy, grew 93% to $694 million. That growth rate signals a second meaningful franchise taking shape alongside the company's oncology anchor. Management then raised its 2026 adjusted EPS range to $2.77–$2.82 from $2.66–$2.76 and lifted the low end of its revenue outlook to $66.8 billion from $66.3 billion. That pairing of a beat and a raise is what turned a good quarter into a 4.5% move.
A strong backdrop for health care stocks added momentum. The sector rose 2.7% on the day even as the Nasdaq fell 1.77%, with Eli Lilly (LLY) gaining 8.65% and Johnson & Johnson (JNJ) adding 2.29% as investors rotated toward defensive earnings. Merck's gain clearly outpaced the more modest advances at Gilead Sciences (GILD), up 1.47%, and Pfizer (PFE), up 0.95%. That gap shows company-specific results, not the sector tide alone, drove the bulk of today's move.
What is the Merck & Co., Inc. Rating - Should I Buy?
Weiss Ratings assigns MRK a C rating. Current recommendation is Hold. That rating balances a set of genuinely strong underlying dimensions against growth and stability profiles that remain middle-of-the-road. Today's results go a long way toward explaining both sides of that balance.
The strengths are substantial. Merck is rated Excellent on the Efficiency Index, the Solvency Index, and the Total Return Index. The trailing 4.76% profit margin and 6.96% ROE look thin on paper. The Efficiency rating looks through those figures to the business generating them. A company that just booked $5.07 billion of GAAP net income on $18.09 billion of quarterly revenue has far more earning power than its trailing margin suggests. The Excellent Solvency rating points to a balance sheet with ample capacity to fund late-stage pipeline work and a dividend yielding 2.41% without strain. The Total Return rating reflects what holders have actually experienced: the stock now trades within roughly 6% of its August high of $156.92.
Where the picture becomes more nuanced is in the Fair ratings on the Growth, Volatility, and Dividend indices. The Growth Index rating reflects 5.07% revenue growth. That is respectable for a company of Merck's scale, but the 3% year-over-year dip in adjusted EPS keeps this dimension from rating higher. The Volatility Index rating fits a stock that can jump 4.51% in a single session on an earnings surprise. That move rewards holders today but shows how sharply the shares can reprice around reporting dates. A Fair Dividend Index rating suggests the payout is steady rather than standout. Together, these three dimensions are what hold the overall rating at C rather than lifting it into Buy territory.
Within the Health Care sector, Merck is on par with Gilead Sciences, Inc. (GILD, C), Pfizer Inc. (PFE, C), and Regeneron Pharmaceuticals, Inc. (REGN, C). Merck's Excellent marks on Efficiency, Solvency, and Total Return give it a strong foundation within that peer group. Today's beat-and-raise gives investors a concrete reason to believe the growth side of the ledger can catch up.
About Merck & Co., Inc.
Merck & Co., Inc. (MRK) is a Health Care company and one of the largest research-driven drugmakers in the world. Headquartered in Rahway, New Jersey, Merck develops and markets prescription medicines, vaccines, and biologic therapies across oncology, infectious disease, cardiovascular, and immunology markets. It also runs a significant Animal Health business serving livestock producers and companion-animal veterinarians.
Oncology is the centerpiece of the portfolio, led by Keytruda, the immunotherapy approved across a broad range of tumor types. Keytruda Qlex, the subcutaneous formulation, extends that franchise with a more convenient administration option. The vaccine business is anchored by Gardasil, Merck's HPV vaccine, alongside the pneumococcal vaccine Capvaxive. In cardiovascular medicine, Winrevair has quickly become a growth engine in pulmonary arterial hypertension, a market where Merck holds a first-in-class position.
Merck's competitive advantages come from its global commercial scale, deep regulatory experience, and an R&D organization capable of advancing a broad pipeline through costly late-stage trials. Its manufacturing footprint and long-standing relationships with health systems and governments worldwide are not easily replicated by smaller players. That scale gives Merck the resources to build new franchises while defending its established blockbusters.
Investor Outlook
Merck & Co., Inc. (MRK) carries a Weiss Rating of C (Hold), and today's beat-and-raise quarter puts real momentum behind a stock already sitting close to its 52-week high of $156.92. Investors should watch whether Keytruda Qlex adoption continues building on its $830 million quarterly contribution, whether Winrevair sustains its triple-digit-adjacent growth, and whether Merck delivers on its raised $2.77–$2.82 adjusted EPS guidance. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--